Related Experiment Video
Updated: Apr 14, 2026
Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
Quetiapine modestly improves sleep and breathing but impairs next day performance in people with OSA and difficulty
Cricket Fauska1, Tarun Bastiampillai1, Georgina Rawson1
1Flinders University, Flinders Health and Medical Research Institute (FHMRI) Sleep Health/Adelaide Institute for Sleep Health (AISH), College of Medicine and Public Health, Adelaide, South Australia, Australia.
Rationale:
Quetiapine is commonly prescribed "off-label" to people with insomnia symptoms. People with undiagnosed obstructive sleep apnea (OSA) frequently report insomnia symptoms, particularly difficulties maintaining sleep. In 2023, 10.7 million prescriptions were dispensed for quetiapine in the United States. Yet, there is limited information regarding the effects of quetiapine on sleep, breathing, and next-day performance in people with OSA.
Objectives:
To determine the effects of 50 mg of quetiapine versus placebo on OSA severity and other polysomnographic parameters plus next day vigilance and driving simulator performance in people with OSA who also reported difficulty maintaining sleep.
Methods:
We performed a double-blind, randomized, placebo-controlled, cross-over study (NCT05303935) in 15 people with OSA and difficulty maintaining sleep. Participants were studied overnight via polysomnography twice ∼1 week apart and received either 50 mg of quetiapine or placebo (order randomized) just prior to sleep. A 10-minute psychomotor vigilance task (PVT) and 30-minute driving simulator test were performed each morning.
Results:
Compared to placebo, quetiapine reduced the apnea/hypopnea index (primary outcome) ([Mean ± SD] 27 ± 16 vs. 20 ± 12 events/h, P = .009), arousal index (32 ± 16 vs. 25 ± 9 arousals/h, P = .012), and increased sleep efficiency (80 ± 11 vs. 87 ± 9%, P < .001) without worsening hypoxemia (mean overnight SpO2 94.7 ± 1.2 vs. 94.5 ± 1.5%, P = .38). However, next morning vigilance (median PVT reaction time 336 ± 48 vs. 382 ± 84 ms, P = .008) and driving simulator performance (steering deviation 72 ± 38 vs. 96 ± 53 cm, P < .01) were significantly impaired with quetiapine.
Conclusions:
Consistent with a hypnotic effect, a single night of low-dose quetiapine reduced OSA severity as measured via the apnea/hypopnea index and increased sleep efficiency without worsening overnight hypoxemia. However, there was evidence of next day impairment in vigilance and driving simulator performance.
Clinical Trial Registration:
NCT05303935.
Primary Source Of Funding:
National Health and Medical Research Council of Australia (1196261).
More Related Videos
Related Concept Videos
01:21Sleep Apnea
The condition is more prevalent among...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:29Anxiolytic Drugs: Benzodiazepines and Buspirone
01:19Management of Insomnia
01:19Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
01:13Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...